Go Pro
→ The only 5 stocks that matter (From TradeSmith) (Ad)tc pixel
LON:SCLP

Scancell Interim Earnings Report

Scancell logo
GBX 9.47 +0.12 (+1.28%)
As of 11:36 AM Eastern
ProfileEarnings History

Scancell EPS Results

Actual EPS
-GBX 0.55
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Scancell Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Scancell Announcement Details

Quarter
Interim
Date
1/29/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Scancell Earnings Headlines

Scancell completes up to US$25m in debt financing
September 24, 2026  |  markets.ft.comhttps://markets.ft.com/data/announce/detail?dockey=1323-17802160-7HJA7H8V0RID58CIK21K1GCPQJ
Scancell Secures Up to US$25 Million BlackRock Loan Facility for iSCIB1+ Phase 3 Programme
September 24, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/scancell-secures-us-25-million-065831339.html
Trump's crypto bank just got approved
Here's a detail almost everyone missed about last October. When crypto stumbled in October 2025, Trump's crypto team was only half built. His SEC chairman was in place. But the man now running the CFTC, crypto's other main regulator, hadn't even been nominated yet. This October is the first where both seats are filled with Trump's own picks, working from the same playbook... And the market already seems to sense it. Bitcoin just posted one of its strongest summers in years, gaining in both August and September. ETF buyers just had their biggest week since last fall. That's the backdrop heading into crypto's favorite month.tc pixel
October 2 at 1:00 AM  |  Crypto 101 Media (Ad)
Scancell Secures Up To $25 Mln Debt Facility To Fund ISCIB1+ Phase 3
September 24, 2026  |  rttnews.comhttps://www.rttnews.com/3693575/scancell-secures-up-to-25-mln-debt-facility-to-fund-iscib1-phase-3.aspx
Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development
September 24, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scancell-completes-up-to-us-25-million-in-debt-financing-providing-optionality-alongside-equity-investment-to-finance-iscib1-phase-3-development-1036569779
Scancell Holdings secures $25m financing as it advances melanoma trial
September 24, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/scancell-holdings-secures-25m-financing-063200583.html
See More Scancell Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Scancell? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scancell and other key companies, straight to your email.

About Scancell

Scancell (LON:SCLP) (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma. The precise patient population that iSCIB1+ brings benefit to, in combination with CPIs, has been identified, enabling precision-biomarker led registrational development. The lead Moditope® peptide active immunotherapy, Modi-1, is being investigated in a Phase 2 study in a broad range of solid tumours and also has shown encouraging interim clinical data. Scancell’s wholly-owned subsidiary, Glymab Therapeutics Ltd., has been established with the intention to develop an exciting early-stage pipeline of high affinity GlyMab® antibodies targeting tumour specific glycans, two of which already have been licensed and are being developed by Genmab A/S.

View Scancell Profile
Earnings Tools